Jianzheng Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jianzheng Liu has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Chao Gao
The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
2 shared publications - Patrick W. Serruys
University of Galway
2 shared publications - Scot Garg
Department of Cardiology Royal Blackburn Hospital Blackburn UK
2 shared publications Aiyuan Cheng
1 shared publicationBin Zhu
1 shared publicationChengxing Shen
Department of Cardiology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine , Shanghai
1 shared publication
Latest Publications
- Open Access
- 4 September 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (36) , e50551
Association of eight urinary metals and trouble sleeping
While toxic heavy metals have been linked to sleep disorders, the role of less-studied metals remains unclear. We aimed to explore the associations of 8 urinary metals with trouble sleeping and to identify potential gender-specific patterns. This study included 10,012 adults from the National Health and Nutrition Examination Survey 2005–2018. Urinary concentrations of tungsten, arsenic, thallium, cesium, antimony, molybdenum, cobalt, and cadmium were measured. Trouble sleeping was self-reported. We employed weighted logistic regression, restricted cubic spline models, and weighted quantile sum regression to evaluate single and mixed-metal effects. Among participants, 50.2% were male and 25.3% reported trouble sleeping. Higher urinary tungsten levels were associated with increased likelihood of trouble sleeping in males (odds ratios: 1.28–1.30). Arsenic, thallium, and cesium showed inverse associations, with notable gender differences. Weighted quantile sum analysis supported the positive association of tungsten and the inverse associations of arsenic and cesium. No significant associations were found for antimony, molybdenum, cobalt, or cadmium. Urinary tungsten is cross-sectionally associated with trouble sleeping in males, while arsenic, thallium, and cesium show inverse associations, with gender-specific patterns. Further research using validated tools is warranted to validate these associations, elucidate the underlying biological mechanisms, and highlight the significance of assessing combined metal exposures in relation to sleep health.
- 4 September 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (36) , e50551
Open AccessAssociation of eight urinary metals and trouble sleeping
While toxic heavy metals have been linked to sleep disorders, the role of less-studied metals remains unclear. We aimed to explore the associations of 8 urinary metals with trouble sleeping and to identify potential gender-specific patterns. This study included 10,012 adults from the National Health and Nutrition Examination Survey 2005–2018. Urinary concentrations of tungsten, arsenic, thallium, cesium, antimony, molybdenum, cobalt, and cadmium were measured. Trouble sleeping was self-reported. We employed weighted logistic regression, restricted cubic spline models, and weighted quantile sum regression to evaluate single and mixed-metal effects. Among participants, 50.2% were male and 25.3% reported trouble sleeping. Higher urinary tungsten levels were associated with increased likelihood of trouble sleeping in males (odds ratios: 1.28–1.30). Arsenic, thallium, and cesium showed inverse associations, with notable gender differences. Weighted quantile sum analysis supported the positive association of tungsten and the inverse associations of arsenic and cesium. No significant associations were found for antimony, molybdenum, cobalt, or cadmium. Urinary tungsten is cross-sectionally associated with trouble sleeping in males, while arsenic, thallium, and cesium show inverse associations, with gender-specific patterns. Further research using validated tools is warranted to validate these associations, elucidate the underlying biological mechanisms, and highlight the significance of assessing combined metal exposures in relation to sleep health.
- Open Access
- 10 February 2026
- Published by Elsevier in SSRN Electronic Journal
Drug-coated balloon versus drug-eluting stent for treating de novo proximal left anterior descending artery lesions: insights from the REC-CAGEFREE I trial
BackgroundThe safety and efficacy of drug-coated balloon (DCB) angioplasty for the treatment of proximal left anterior descending (LAD) lesions remain unclear. We aim to assess the prognosis of DCB versus drug-eluting stent (DES) in treating de novo proximal LAD lesions.MethodsREC-CAGEFREE I was an investigator-initiated, multi-center, non-inferiority trial that randomized 2,272 patients to paclitaxel-coated balloon with the option of rescue stenting or second-generation sirolimus-eluting stents for treating de novo lesions, regardless of vessel diameter. In this pre-specified subgroup analysis of the REC-CAGEFREE I study, patients were stratified into two groups based on whether target lesion was located in proximal LAD. The primary endpoint was device-oriented composite endpoint (DoCE, a composite of cardiovascular death, target vessel myocardial infarction, and clinically and physiologically indicated target lesion revascularization) at 2 years.ResultsOf 2,272 patients randomized, 688 (30.3%) had target lesion in proximal LAD. In patients with proximal LAD lesions, compared to DES treatment, DCB treatment had a higher risk of 2-year DoCE (8.8% versus 3.4%, HRIPTW:2.68, 95%CI:1.34-5.35, P=0.008). Similar results were observed in patients with non-proximal LAD lesions (DCB versus DES: 5.4% versus 3.3%, HRIPTW:1.72, 95%CI:1.04-2.85, P=0.038). No significant interaction was observed between the lesion location and the treatment strategy (DES/DCB) (Pinteraction=0.257). In patients with DCB treatment, proximal LAD had a higher risk of DoCE compared to non-proximal LAD (8.8% vs. 5.4%, HRIPTW:1.68, 95%CI:1.01-2.81, P=0.049).ConclusionsDCB treatment was associated with a higher risk of 2-year DoCE compared to DES treatment in patients with target lesion in proximal LAD.
- 10 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDrug-coated balloon versus drug-eluting stent for treating de novo proximal left anterior descending artery lesions: insights from the REC-CAGEFREE I trial
BackgroundThe safety and efficacy of drug-coated balloon (DCB) angioplasty for the treatment of proximal left anterior descending (LAD) lesions remain unclear. We aim to assess the prognosis of DCB versus drug-eluting stent (DES) in treating de novo proximal LAD lesions.MethodsREC-CAGEFREE I was an investigator-initiated, multi-center, non-inferiority trial that randomized 2,272 patients to paclitaxel-coated balloon with the option of rescue stenting or second-generation sirolimus-eluting stents for treating de novo lesions, regardless of vessel diameter. In this pre-specified subgroup analysis of the REC-CAGEFREE I study, patients were stratified into two groups based on whether target lesion was located in proximal LAD. The primary endpoint was device-oriented composite endpoint (DoCE, a composite of cardiovascular death, target vessel myocardial infarction, and clinically and physiologically indicated target lesion revascularization) at 2 years.ResultsOf 2,272 patients randomized, 688 (30.3%) had target lesion in proximal LAD. In patients with proximal LAD lesions, compared to DES treatment, DCB treatment had a higher risk of 2-year DoCE (8.8% versus 3.4%, HRIPTW:2.68, 95%CI:1.34-5.35, P=0.008). Similar results were observed in patients with non-proximal LAD lesions (DCB versus DES: 5.4% versus 3.3%, HRIPTW:1.72, 95%CI:1.04-2.85, P=0.038). No significant interaction was observed between the lesion location and the treatment strategy (DES/DCB) (Pinteraction=0.257). In patients with DCB treatment, proximal LAD had a higher risk of DoCE compared to non-proximal LAD (8.8% vs. 5.4%, HRIPTW:1.68, 95%CI:1.01-2.81, P=0.049).ConclusionsDCB treatment was associated with a higher risk of 2-year DoCE compared to DES treatment in patients with target lesion in proximal LAD.
- Open Access
- 3 February 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (2)
Three-year clinical outcomes of left atrial appendage occlusion with or without ablation: insight from the RECORD study
The long-term impact of left atrial appendage occlusion (LAAO) plus ablation for atrial fibrillation remains controversial. The present study aims to compare the three-year clinical outcomes of LAAO patients with or without one-staged ablation. The RECORD study (NCT03917563) was a prospective registry conducted in 39 participating sites in China between 1 April 2019 and 31 October 2020, which consecutively enrolled 3082 patients who successfully received the WATCHMAN LAAO device. The current study compared patients who received LAAO only to patients who underwent LAAO plus ablation. A 1:1 propensity score matching was performed to attenuate confounding. The primary outcome was a composite endpoint of cardiovascular death, stroke, and systemic embolism at 3-year. 1633/2928 (55.8%) patients received LAAO only and 1295/2928 (44.2%) received LAAO plus ablation. After propensity score matching, 1016/2032 (50.0%) were in the LAAO group and 1016/2032 (50.0%) in the LAAO plus ablation group. The mean ± SD age was 68.8 ± 9.3 years, with 815 (40.1%) participants being female. The mean ± SD CHA2DS2-VASc and HAS-BLED scores at baseline were 3.9 ± 1.8 and 2.4 ± 1.1, respectively. At three-year, compared to LAAO only, LAAO plus ablation was associated with a lower risk of cardiovascular death, stroke, systemic embolism (6.9%vs.10.4%, HRPSM:0.66, 95%CI: 0.49–0.89, P = 0.007), which was driven mainly by the lower risk of cardiovascular death (3.7% vs. 7.3%, HRPSM: 0.50, 95%CI: 0.34–0.74, P = 0.001). No significant between-group differences were noted for BARC-defined bleeding. LAAO plus ablation was associated with a lower risk of a composite of cardiovascular death, stroke, and systemic embolism than LAAO only at 3-year. However, given the observational nature of the current study, the results should be considered as hypothesis-generating only.
- 3 February 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (2)
Open AccessThree-year clinical outcomes of left atrial appendage occlusion with or without ablation: insight from the RECORD study
The long-term impact of left atrial appendage occlusion (LAAO) plus ablation for atrial fibrillation remains controversial. The present study aims to compare the three-year clinical outcomes of LAAO patients with or without one-staged ablation. The RECORD study (NCT03917563) was a prospective registry conducted in 39 participating sites in China between 1 April 2019 and 31 October 2020, which consecutively enrolled 3082 patients who successfully received the WATCHMAN LAAO device. The current study compared patients who received LAAO only to patients who underwent LAAO plus ablation. A 1:1 propensity score matching was performed to attenuate confounding. The primary outcome was a composite endpoint of cardiovascular death, stroke, and systemic embolism at 3-year. 1633/2928 (55.8%) patients received LAAO only and 1295/2928 (44.2%) received LAAO plus ablation. After propensity score matching, 1016/2032 (50.0%) were in the LAAO group and 1016/2032 (50.0%) in the LAAO plus ablation group. The mean ± SD age was 68.8 ± 9.3 years, with 815 (40.1%) participants being female. The mean ± SD CHA2DS2-VASc and HAS-BLED scores at baseline were 3.9 ± 1.8 and 2.4 ± 1.1, respectively. At three-year, compared to LAAO only, LAAO plus ablation was associated with a lower risk of cardiovascular death, stroke, systemic embolism (6.9%vs.10.4%, HRPSM:0.66, 95%CI: 0.49–0.89, P = 0.007), which was driven mainly by the lower risk of cardiovascular death (3.7% vs. 7.3%, HRPSM: 0.50, 95%CI: 0.34–0.74, P = 0.001). No significant between-group differences were noted for BARC-defined bleeding. LAAO plus ablation was associated with a lower risk of a composite of cardiovascular death, stroke, and systemic embolism than LAAO only at 3-year. However, given the observational nature of the current study, the results should be considered as hypothesis-generating only.